Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients

References

• Chokotho L, Harrison WJ, Lubega N, Mkandawire NC. Avascular necrosis of the femoral head in HIV positive patients-an assessment of risk factors and early response to surgical treatment. Malawi Med J 2013;25:28–32.
   PubMed Web of Science ®Google Scholar
• Pouya F, Kerachian MA. Avascular necrosis of the femoral head: are any genes involved? Arch Bone Jt Surg 2015;3:149–55.
   PubMedGoogle Scholar
• Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004;15:457–75.
   PubMed Web of Science ®Google Scholar
• Liu C, Walter TS, Huang P, et al. Structural and functional insights of RANKL-RANK interaction and signaling. J Immunol 2010;184:6910–19.
   PubMed Web of Science ®Google Scholar
• Udagawa N, Takahashi N, Yasuda H, et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000;141:3478–84.
   PubMed Web of Science ®Google Scholar
• Itonaga I, Fujikawa Y, Sabokbar A, et al. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 2000;192:97–104.
   PubMed Web of Science ®Google Scholar
• Xing L, Bushnell TP, Carlson L, et al. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 2002;17:1200–10.
   PubMed Web of Science ®Google Scholar
• Iotsova V, Caamaño J, Loy J, et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997;3:1285–9.
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–76.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329–37.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang Y, Chen W, et al. Achyranthes bidentata extract exerts osteoprotective effects on steroid-induced osteonecrosis of the femoral head in rats by regulating RANKL/RANK/OPG signaling. J Transl Med 2014;12:334.
   PubMed Web of Science ®Google Scholar
• Grimaud E, Soubigou L, Couillaud S, et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 2003;163:2021–31.
   PubMed Web of Science ®Google Scholar
• Sen RK. Management of avascular necrosis of femoral head at pre-collapse stage. Indian J Orthop 2009;43:6–16.
   PubMed Web of Science ®Google Scholar
• Reis ND, Schwartz O, Militianu D, et al. Hyperbaric oxygen therapy as a treatment for stage-I avascular necrosis of the femoral head. J Bone Joint Surg Br 2003;85:371–5.
   PubMedGoogle Scholar
• Camporesi EM, Vezzani G, Bosco G, et al. Hyperbaric oxygen therapy in femoral head necrosis. J Arthroplasty 2010;25:118–23.
   PubMed Web of Science ®Google Scholar
• Bennett M. Hyperbaric oxygen therapy improved both pain scores and range of motion in patients with early idiopathic femoral head necrosis (Ficat stage II). Diving Hyperb Med 2011;41:105.
   PubMed Web of Science ®Google Scholar
• Al Hadi H, Smerdon GR, Fox SW. Hyperbaric oxygen therapy accelerates osteoblast differentiation and promotes bone formation. J Dent 2015;43:382–8.
   PubMed Web of Science ®Google Scholar
• Al Hadi H, Smerdon GR, Fox SW. Hyperbaric oxygen therapy suppresses osteoclast formation and bone resorption. J Orthop Res 2013;31:1839–44.
   PubMed Web of Science ®Google Scholar
• Ficat RP. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J Bone Joint Surg Br 1985;67:3–9.
   PubMed Web of Science ®Google Scholar
• Vande Berg BC, Poilvache P, Duchateau F, et al. Lesions of the menisci of the knee: value of MR imaging criteria for recognition of unstable lesions. AJR Am J Roentgenol 2001;176:771–6.
   PubMed Web of Science ®Google Scholar
• Ohzono K, Saito M, Takaoka K, et al. Natural history of nontraumatic avascular necrosis of the femoral head. J Bone Joint Surg Br 1991;73:68–72.
   PubMed Web of Science ®Google Scholar
• Koren L, Ginesin E, Melamed Y, et al. Hyperbaric oxygen for stage I and II femoral head osteonecrosis. Orthopedics 2015;38:e200–5.
   PubMed Web of Science ®Google Scholar
• Samara S, Dailiana Z, Chassanidis C, et al. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis. Exp Mol Pathol 2014;96:9–14.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang K, Shi Z, Zhang M. Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2008;22:1161–4.
   PubMedGoogle Scholar
• Weaver LK. Hyperbaric oxygen therapy indications. 13th ed. Durham: Committee Report: Undersea and Hyperbaric Medical Society Press; 2014.
   Google Scholar
• Camporesi EM, Bosco G. Mechanisms of action of hyperbaric oxygen therapy. Undersea Hyperb Med. 2014;41:247–52.
   PubMed Web of Science ®Google Scholar
• Mutluoglu M, Sonmez G, Sivrioglu AK, Ay H. There may be a role for hyperbaric oxygen therapy in transient osteoporosis of the hip. Acta Orthop Belg 2012;78:685–7.
   PubMed Web of Science ®Google Scholar
• Strauss M, Dvorak T, Melamed Y, Reis DN. Femoral head necrosis and hyperbaric oxygen therapy. In: Hyperbaric Medicine Practice. Z Orthop Unfall 2015;153:488–97.
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–19.
   PubMed Web of Science ®Google Scholar
• Yano K, Isuke Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999;14:518–27.
   PubMed Web of Science ®Google Scholar
• Dougall WC, Glaccum M, Rohrbach K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412–24.
   PubMed Web of Science ®Google Scholar
• Miao Q, Hao S, Li H, et al. Expression of osteoprotegerin, RNAK and RANKL genes in femoral head avascular necrosis and related signaling pathway. Int J Clin Exp Pathol 2015;8:10460–7.
   PubMed Web of Science ®Google Scholar
• Silva ML, Tasso L, Azambuja AA, et al. Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy histomorphometric and immunohistochemical analysis. Clin Oral Investig 2017;21:199–210.
   PubMed Web of Science ®Google Scholar
• Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304–9.
   PubMed Web of Science ®Google Scholar
• Okazaki S, Nishitani Y, Nagoya S, et al. Femoral head osteonecrosis can be caused by disruption of the systemic immune response via the toll-like receptor 4 signalling pathway. Rheumatology (Oxford) 2009;48:227–32.
   PubMed Web of Science ®Google Scholar
• Pietschmann P, Mechtcheriakova D, Meshcheryakova A, et al. Immunology of osteoporosis: a mini-review. Gerontology 2016;62:128–37.
   PubMed Web of Science ®Google Scholar
• Gadd MA, McClellan DS, Neuman TS, Hansbrough JF. Effect of hyperbaric oxygen on murine neutrophil and T-lymphocyte functions. Crit Care Med 1990;18:974–9.
   PubMed Web of Science ®Google Scholar